Abstract
The regulation of cell therapy and gene therapy products is a major challenge for the Brazilian state. From a legal point of view, the legislative apparatus, including constitutional, prohibits the marketing and patent of human substances. From the point of view of the organization of the state bureaucracy, the responsibilities for the regulation of research and application of these technologies in humans may involve up to four different institutions. The National Agency for Health Surveillance (ANVISA) has been the protagonist in structuring the regulation of cell therapy and gene therapy in Brazil, and steps have been taken to ensure quality of these products. However, obstacles such as the commercialization of these therapies and the need to determine whether these products will be regulated following the assumptions adopted in Brazil for drugs and biological products or for human blood and tissues still remain.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
ANVISA. Board Resolution 153 June 14, 2004. http://portal.anvisa.gov.br/wps/wcm/connect/4bc8428047457945865fd63fbc4c6735/rdc_153.pdf?MOD=AJPERES. Accessed 29 Dec 2014
Institutional Technical Reports (2010) Ministry of Health. Cell therapy and stem cells research funding in Brazil. Rev Saude Publica 44(4):763–764
Brazil. Law 11,105 of March 25, 2005. http://www.planalto.gov.br/ccivil_03/_ato2004-2006/2005/lei/l11105.htm. Accessed 15 Dec 2014
Brazil. Decree 5,591 of November 22, 2005. http://www.planalto.gov.br/ccivil_03/_ato2004-2006/2005/Decreto/D5591.htm. Accessed 15 Dec 2014
ANVISA. Ordinance 498 of July 3, 2007. Official Gazette
ANVISA. Board Resolution #9 of March 16, 2011. http://portal.anvisa.gov.br/wps/wcm/connect/623ecb0047458efe9836dc3fbc4c6735/RDC_09_2011.pdf?MOD=AJPERES. Accessed 15 Dec 2014
Brazil. Constitution of the Federative Republic of Brazil, 3rd edn. http://www.stf.jus.br/repositorio/cms/portalStfInternacional/portalStfSobreCorte_en_us/anexo/constituicao_ingles_3ed2010.pdf. Accessed 15 Dec 2014
Brazil. Law 9,279 of May 14, 1996. http://www.planalto.gov.br/ccivil_03/leis/l9279.htm. Accessed 15 Dec 2014
ANVISA. Ordinance 1,700 in December 12, 2012. Official Gazette
ANVISA. Board Resolution 56 of December 16, 2010. http://portal.anvisa.gov.br/wps/wcm/connect/c8272000474597529fcadf3fbc4c6735/RDC_n%C2%BA_56.pdf?MOD=AJPERES. Accessed 15 Dec 2014
National Council of Heath. Resolution 466 of December 12, 2012. http://conselho.saude.gov.br/resolucoes/2012/466_english.pdf. Accessed 29 Dec 2014
Disclaimer
The stream of arguments, findings, and conclusions are the author’s entire responsibility, not necessarily expressing the institutional definitions of the ANVISA, Ministry of Health, and the Federal Government of Brazil.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 American Society of Gene and Cell Therapy
About this chapter
Cite this chapter
de Freitas, D.R.C. (2015). The Regulatory Pathway for Advanced Cell Therapy and Gene Therapy Products in Brazil: A Road to Be Built. In: Galli, M., Serabian, M. (eds) Regulatory Aspects of Gene Therapy and Cell Therapy Products. Advances in Experimental Medicine and Biology(), vol 871. Springer, Cham. https://doi.org/10.1007/978-3-319-18618-4_12
Download citation
DOI: https://doi.org/10.1007/978-3-319-18618-4_12
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-18617-7
Online ISBN: 978-3-319-18618-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)